Skip to main content
SpringerLink
Log in

The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder

  • Published:
World Journal of Urology Aims and scope Submit manuscript

Summary

Successful management of transitional-cell carcinoma of the urinary bladder is greatly dependent upon regular surveillance and early detection of persistent or recurrent carcinoma. The development of a highly sensitive urinary test for the detection of transitional-cell carcinoma of the bladder could have a dramatic impact on our ability to diagnose and monitor bladder cancer patients as well as influence the treatment outcome. The urinary level of the nuclear matrix protein, NMP22, has been found to be elevated in patients with urothelial malignancy. This has prompted the development of an immunoassay to quantitate urinary NMP22 and use it as a cancer-specific marker. We provide a summary of the studies completed with the immunoassay for urinary NMP22 as an indicator for the presence of transitional-cell carcinoma and compare the results with those obtained using other screening modalities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Badalament RA, Hermansen DK, Kimmel M, Gay H, Herr HW, Fair WR, Whitmore WE, Melamed MR (1987) The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 60: 1423–1427

    Google Scholar 

  2. Berezney R (1991) The nuclear matrix: a heuristic model for investigating genomic organization and function in the cell nucleus. J Cell Biochem 47: 109–123

    Google Scholar 

  3. Berezney R, Coffey DS (1974) Identification of a nuclear matrix protein. Biochem Biophys Res Commun 60: 1410–1416

    Google Scholar 

  4. Bidwell JP, Fey EG, Wijnen AJ van, Penman S, Stein JL, Lian JB, Stein GS (1994) Nuclear matrix proteins distinguish normal diploid osteoblasts from osteosarcoma cells. Cancer Res 54: 28–32

    Google Scholar 

  5. Billery C, Lamy B, Bittard H, Rozan S, Carbillet JP (1993) Flow cytometry versus urinary cytology in the diagnosis and follow-up of bladder tumors: critical review of a 5-year experience.World J Urol 11: 156–160

    Google Scholar 

  6. Bonner RB, Hemstreet GP, Fardet Y, Rao JY, Min KW, Hurst RE (1993) Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells. Cancer 72: 2461–2469

    Google Scholar 

  7. Boring CC, Squires TS, Tong T (1995) J Cancer Res Clin Oncol 45: 8

    Google Scholar 

  8. Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL, Lange PH, Messing EM, Pasciak RM, Reservitz GB, Ross RN, Rukstalis DB, Sarosdy ME, Soloway MS, Thiel RP, Vogelzang NJ, Hayden CL (1996) Urinary nuclear matrix protein (NMP22) as a marker for transitional cell carcinoma of the urinary tract. J Urol (in press)

  9. Chopin DK, deKernion JB, Rosenthal DL, Fahey JL (1985) Monoclonal antibodies against transitional cell carcinoma for detection of malignant urothelial cells in bladder washing. J Urol 134: 260–265

    Google Scholar 

  10. Compton DA, Clevland DW (1993) NuMA is required for the proper completion of mitosis. J cell Biol 120: 947–957

    Google Scholar 

  11. Cordon-Cardo C, Reuter VE, Lloyd KO, Sheinfeld J, Fair WR, Old LJ, Melamed MR (1988) Blood group-related antigens in human urothelium: enhanced expression of precursor, Lex and Ley determinants in urothelial carcinoma. Cancer Res 48: 4113–4120

    Google Scholar 

  12. Dworetzky SI, Fey EG, Penman S, Lian JB, Stein JL, Stein GS (1990) Progressive changes in the protein composition of the nuclear matrix during rat osteoblast differentiation. Proc Natl Acad Sci USA 87: 4605–4609

    Google Scholar 

  13. Farrow GM. Urine cytology in the detection of bladder cancer: a critical approach. J Occup Med 32: 817–821

  14. Fey EG, Penman S (1988) Nuclear matrix proteins reflect cell type of origin in cultured human cells. Proc Natl Acad Sci USA 85: 121–125

    Google Scholar 

  15. Golijanin D, Sherman Y, Shapiro A, Pode D (1995) Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine. Urology 46: 173–177

    Google Scholar 

  16. International Union Against Cancer (1982) TNM classification of malignant tumours, 3rd edn. Springer, Berlin Heidelberg, New York

    Google Scholar 

  17. Keesee K, Briggman JB, Thiel G, Wu YJ (1996) Utilization of nuclear matrix proteins for cancer diagnosis. CRC Crit Rev Eukaryotic Gene Expr 6: 189–214

    Google Scholar 

  18. Khanuja PS, Lehr JE, Soule HD, Gehani SK, Noto AC, Choudhury S, Chen R, Pienta KJ (1993) Nuclear matrix proteins in normal and breast cancer cells. Cancer Res 53: 3394–3398

    Google Scholar 

  19. Leyh H, Mazeman E, Hall RR, Bennett AH (1996) Results of a European multicenter trial comparing the Bard BTA test to urine cytology in patients suspected of having bladder cancer. Abstract presented at the 1996 American Urological Association

  20. Raghaven D, Shipley WU, Gernick MB (1990) Biology and the management of bladder cancer. N Engl J Med 322: 1129–1138

    Google Scholar 

  21. Sarosdy MF, deVere White RW, Soloway MS, Sheinfeld J, Hudson MA. Schellhammer PF, Jarowenko MV, Adams G, Blumenstein BA (1995) Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 154: 379–384

    Google Scholar 

  22. Smetana K, Steele WJ, Busch H (1963) Exp Cell Res 31: 198–201

    Google Scholar 

  23. Soloway MS, Briggman JV, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange P, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL (1996) Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 156: 363–367

    Google Scholar 

  24. Weiner HG, Vooijs GP, Hof-Ggrootenboer B van't (1993) Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol (Baltimore) 37: 163–169

    Google Scholar 

  25. Yang CH, Lambie EJ, Snyder M (1992) NuMA: an unusually long coiled-coil related protein in the mammalian nucleus. J Cell Biol 116: 1303–1317

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Miami School of Medicine, P.O. Box 016960(M814), 33101, Miami, FL, USA

    Scott W. Shelfo & Mark S. Soloway

Authors
  1. Scott W. Shelfo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark S. Soloway
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shelfo, S.W., Soloway, M.S. The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder. World J Urol 15, 107–111 (1997). https://doi.org/10.1007/BF02201981

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02201981

Keywords

Search

Navigation